A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease

Trial Profile

A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs MP4CO (Primary) ; Sodium chloride
  • Indications Sickle cell anaemia; Veno-occlusive disorders
  • Focus Therapeutic Use
  • Sponsors Sangart
  • Most Recent Events

    • 03 Aug 2017 This trial has been discontinued in Belgium.
    • 24 Sep 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2013-001600-11).
    • 04 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top